Gastrostomy	B:C0017196
in	O
patients	O
with	O
prion	O
disease	I:C0162534
.	O

Gastrostomy	O
in	O
patients	O
with	O
prion	B:C0162534
disease	I:C0162534
.	O

Patients	O
with	O
prion	B:C0162534
diseases	I:C0162534
can	O
live	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
state	O
of	O
akinetic	O
mutism	I:C0001889
given	O
appropriate	O
management	O
of	I:C1536570
their	I:C1536570
symptoms	I:C1536570
.	O

Patients	O
with	O
prion	O
diseases	I:C0162534
can	O
live	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
state	O
of	O
akinetic	B:C0001889
mutism	I:C0001889
given	O
appropriate	O
management	O
of	I:C1536570
their	I:C1536570
symptoms	I:C1536570
.	O

Patients	O
with	O
prion	O
diseases	I:C0162534
can	O
live	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
state	O
of	O
akinetic	O
mutism	I:C0001889
given	O
appropriate	O
management	B:C1536570
of	I:C1536570
their	I:C1536570
symptoms	I:C1536570
.	O

To	O
study	O
symptom	B:C1457887
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	O
on	O
3	O
patients	O
with	O
V180I	O
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	O
by	I:C0041281
tube	I:C0041281
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	B:C0017196
on	O
3	O
patients	O
with	O
V180I	O
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	O
by	I:C0041281
tube	I:C0041281
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	O
on	O
3	O
patients	O
with	O
V180I	B:C0022336
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	O
by	I:C0041281
tube	I:C0041281
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	O
on	O
3	O
patients	O
with	O
V180I	O
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	B:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	O
by	I:C0041281
tube	I:C0041281
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	O
on	O
3	O
patients	O
with	O
V180I	O
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	B:C0278249
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	O
by	I:C0041281
tube	I:C0041281
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	O
on	O
3	O
patients	O
with	O
V180I	O
genetic	I:C0022336
Creutzfeldt	I:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
(	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	B:C0041281
by	I:C0041281
tube	I:C0041281
.	O

In	O
the	O
3	O
gastrostomy	B:C0017196
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	B:C4032686
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	B:C0017196
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	B:C0041281
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	B:C0457454
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	B:C0041281
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	B:C0574032
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	O
complications	I:C3495031
.	O

In	O
the	O
3	O
gastrostomy	O
cases	O
,	O
there	O
were	O
no	O
direct	I:C4032686
complications	I:C4032686
due	O
to	O
the	O
gastrostomy	O
or	O
tube	O
feeding	I:C0041281
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	O
feeding	I:C0041281
or	O
initiation	O
of	I:C0574032
continuous	I:C0574032
drip	I:C0574032
infusion	I:C0574032
due	O
to	O
severe	B:C3495031
complications	I:C3495031
.	O

Antibiotics	B:C0199779
were	I:C0199779
administered	I:C0199779
for	O
mild	O
infections	I:C0004623
,	O
a	O
complication	O
of	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	O
being	O
used	O
for	O
intravenous	O
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

Antibiotics	O
were	I:C0199779
administered	I:C0199779
for	O
mild	B:C0004623
infections	I:C0004623
,	O
a	O
complication	O
of	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	O
being	O
used	O
for	O
intravenous	O
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

Antibiotics	O
were	I:C0199779
administered	I:C0199779
for	O
mild	O
infections	I:C0004623
,	O
a	O
complication	O
of	O
Creutzfeldt	B:C0022336
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	O
being	O
used	O
for	O
intravenous	O
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

Antibiotics	O
were	I:C0199779
administered	I:C0199779
for	O
mild	O
infections	I:C0004623
,	O
a	O
complication	O
of	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	B:C0017196
being	O
used	O
for	O
intravenous	O
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

Antibiotics	O
were	I:C0199779
administered	I:C0199779
for	O
mild	O
infections	I:C0004623
,	O
a	O
complication	O
of	O
Creutzfeldt	O
-	I:C0022336
Jakob	I:C0022336
disease	I:C0022336
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	O
being	O
used	O
for	O
intravenous	B:C0348016
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

We	O
compared	O
the	O
present	O
patient	O
series	O
with	O
that	O
of	O
our	O
previous	O
report	O
statistically	O
,	O
and	O
found	O
that	O
patients	O
undergoing	O
gastrostomy	B:C0017196
required	O
significantly	O
fewer	O
discontinuations	O
of	O
tube	O
feeding	I:C0041281
than	O
those	O
who	O
did	O
not	O
.	O

We	O
compared	O
the	O
present	O
patient	O
series	O
with	O
that	O
of	O
our	O
previous	O
report	O
statistically	O
,	O
and	O
found	O
that	O
patients	O
undergoing	O
gastrostomy	O
required	O
significantly	O
fewer	O
discontinuations	B:C0457454
of	O
tube	O
feeding	I:C0041281
than	O
those	O
who	O
did	O
not	O
.	O

We	O
compared	O
the	O
present	O
patient	O
series	O
with	O
that	O
of	O
our	O
previous	O
report	O
statistically	O
,	O
and	O
found	O
that	O
patients	O
undergoing	O
gastrostomy	O
required	O
significantly	O
fewer	O
discontinuations	O
of	O
tube	B:C0041281
feeding	I:C0041281
than	O
those	O
who	O
did	O
not	O
.	O

No	O
significant	O
difference	O
in	O
antibiotic	B:C0199779
administration	I:C0199779
was	O
found	O
between	O
groups	O
,	O
however	O
.	O

It	O
is	O
our	O
conclusion	O
that	O
gastrostomy	B:C0017196
should	O
be	O
allowed	O
for	O
symptom	O
support	O
in	O
akinetic	O
patients	O
with	O
prion	O
disease	I:C0162534
,	O
but	O
adequate	O
informed	O
consent	O
must	O
be	O
provided	O
to	O
the	O
patient	O
's	O
family	O
.	O

It	O
is	O
our	O
conclusion	O
that	O
gastrostomy	O
should	O
be	O
allowed	O
for	O
symptom	B:C1457887
support	O
in	O
akinetic	O
patients	O
with	O
prion	O
disease	I:C0162534
,	O
but	O
adequate	O
informed	O
consent	O
must	O
be	O
provided	O
to	O
the	O
patient	O
's	O
family	O
.	O

It	O
is	O
our	O
conclusion	O
that	O
gastrostomy	O
should	O
be	O
allowed	O
for	O
symptom	O
support	O
in	O
akinetic	O
patients	O
with	O
prion	B:C0162534
disease	I:C0162534
,	O
but	O
adequate	O
informed	O
consent	O
must	O
be	O
provided	O
to	O
the	O
patient	O
's	O
family	O
.	O

